US › Healthcare

Ionis Pharmaceuticals Inc (IONS)

US · Healthcare · Biotechnology

$55.07+1.06%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$267.9M
Revenue YoY
-40.7%
Net profit
$-114.6M
Profit YoY
-192.8%
EPS
$-0.70
EPS estimate
$-1.09
Net margin
-42.8%

EPS came in at -0.70 against a street estimate of -1.09 — a beat of 35.8%.

Key statistics

Market cap
$8.60B
Forward P/E
90.9
P/B
19.56
Book value
$2.65
EPS (TTM)
$-3.48
52-week high
$86.74
52-week low
$40.03
50-day MA
$69.45
200-day MA
$75.17
Beta
0.36

Analyst view

Analysts rate Ionis Pharmaceuticals Inc a buy (17 buy, 8 hold, 1 sell out of 26) with an average price target of $89.14.

Shareholding

Insiders
0.61%
Institutions
106.94%

Largest institutional holders

FundStake
FMR Inc14.78%
Capital World Investors12.75%
BlackRock Inc6.28%
Vanguard Portfolio Management, LLC4.70%
Vanguard Capital Management, LLC4.28%
Wellington Management Company LLP3.85%
T. Rowe Price Investment Management,Inc.3.71%
Two Sigma Investments LLC3.52%

Recent filings & reports

DocumentDate
Quarterly report · Q2 20262026-07-29
Results announced · Q3 20262026-07-29
Reg FD disclosure · Q3 20262026-07-10
Reg FD disclosure · Q3 20262026-07-09
Reg FD disclosure · Q2 20262026-06-24
Quarterly report · Q1 20262026-04-29
Proxy statement · Q2 20262026-04-23
Annual report FY20252026-02-26

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Ionis Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.